Transcription profiling of human untreated and fenretinide-treated CD34+ cells from 4 CML patients

ABSTRACT: Imatinib therapy is first-line treatment for chronic myeloid leukemia (CML), and its failure to target CML progenitor/stem cells may lead to an increased risk of relapse. We report here that fenretinide, a well-tolerated vitamin A derivative, is capable of eradicating primitive CML progenitor/stem cells and significantly enhances the efficacy of imatinib at physiologically achievable concentrations. As tested by colony forming cell assays, formation of various colonies derived primitive CML CD34+ cells was significantly suppressed by fenretinide, particularly with respect to the formation of colonies derived from erythroid progenitors and more primitive CML progenitor/stem cells. Also, fenretinide significantly enhanced the ability of imatinib to suppress the formation of the colonies. Mor

ORGANISM(S): Homo sapiens

SUBMITTER: Hai Fang 

PROVIDER: E-GEOD-17480 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress